Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: A single-institution phase II study

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 651-655

  Charpidou, Andriani ^a   Tsagouli, Sophia ^a   Tsimpoukis, Sotirios ^a   Vassias, Antonios ^a   Makrilia, Nektaria ^a   Stratakos, Grigorios ^a   Gkiozos, Ioannis ^a   Syrigos, Kostas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carboplatin; Etoposide; First line chemotherapy; Irinotecan; Small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CARBOPLATIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; LACTATE DEHYDROGENASE; LOPERAMIDE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER METASTASIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERITONITIS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 77953543690     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283393718     Document Type: Article

References (24)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539-4544.
2. Murren J, Glatstein E, Pass HI. Small-cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Willians & Wilkins; 2001. pp. 983-1018.
3. Aupé rin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al.; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476-484.
4. Pujol JL, Carestia L, Daurè s JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of cisplatincontaining regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83:8-15.
5. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al.; A Hellenic Co-operative Group study. Randomized comparison of etoposide-cisplatin vs. etoposide carboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994; 5:601-607.
6. Lassen U, Kristjansen PE, Osterlind K, Bergman B, Sigsgaard TC, Hirsch FR, et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer, a randomized trial with 5 years follow up. Ann Oncol 1996; 7:356-371.
7. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. A phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1430-1435.
8. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12:463-470.
9. Niell HB, Herndon JE, Miller AA, Watson DM, Sandier AB, Kelly K, et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 2002; 21:293a.
10. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
11. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530-2535.
12. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000; 28:173-185.
13. Therasse P, Arbuck SC, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
14. Smit EF, Fokkema E, Biesma B, Groen HJ, SnoekW, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77:347-351.
15. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441-5447.
16. Eckardt JR, von Pawel J, Papai Z, Tomova A, Crofts TE, Brannon S, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24:2044-2051.
17. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease smallcell lung cancer. J Clin Oncol 2006; 24:2038-2043.
18. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26:4261-4267.
19. Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003; 14:709-714.
20. Pectasides D, Samantas E, Fountzilas G, Briasoulis E, Kosmidis P, Skarlos D, et al. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: a phase II study of the Hellenic Co-operative Oncology Group. Lung Cancer 2007; 58:355-361.
21. Kelly K, Lovato L, Bunn PA Jr, Livingston RB, Zangmeister J, Taylor SA, et al. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res 2001; 7:2325-2329.
22. Hainsworth JD, Morrissey LH, Scullin DC Jr, Houston GA, Prasthofer EF, Gray JR, et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002; 94:2426-2433.
23. Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM edition. J Thorac Oncol 2009; 4:300-310.
24. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2:1067-1077.